



March 2006 BIOTECH SEMINAR

presented and sponsored by:
THE NORTH AMERICA TAIWANESE ENGINEERS' ASSOCIATION'S
~SIG BIOTECH~

PRESENTATIONS:

“Biotech and Drug Development in Taiwan”

DATE: Friday, March 31 2006

TIME: 6:30 PM

LOCATION: Squire Sanders Law Firm
600 Hansen Way, Palo Alto, CA 94304

REGISTRATION: FREE for NATEA members, \$5 for non-members, pizza/ soft drink
RSVP: ysyang@stanford.edu or slcheng1@yahoo.com

SPEAKER'S BIO:

A native of rural Taiwan, Dr. Hong was educated at Taiwan Cheng Kung University, the University of Texas at El Paso, and the University of California at Berkeley. From the last he earned a Ph.D. in chemistry. He went on to do postdoctoral research at Stanford University and was a research scientist at the University of California, San Francisco for twenty years.

Dr. Hong is a pioneer in explicating the structure and function of biomembranes and the effects of long-term exposure to general anesthetics. His longstanding interest in improving cancer therapy has led to a series of breakthroughs in drug carrier technology for improving drug and gene delivery. This line of research has resulted a number of patents and been recognized with 2005 Pioneering Technology Innovation Award(產業科技發展獎個人成就獎—前瞻技術創新) from Taiwan Ministry of Economic Affairs. After being a consultant to several biotech companies, Dr. Hong founded Taiwan Liposome Company in Taiwan and co-founded Hermes Biosciences in the United States. He currently serves as Chairman & CEO of Taiwan Liposome Company and its US subsidiary, TLC Biopharmaceuticals.

Dr. Hong has authored or coauthored more than a hundred scientific publications, including two social science books on Taiwanese Culture, Taiwanese Society. In 2005 he delivered the inaugural James W. Whalen Memorial Chemistry Lecture at University of Texas, El Paso.

This talk will cover mostly updates of TLC Biopharmaceuticals in Taiwan and USA in terms of new product developments and cross Pacific business model.

